CA2208924A1 - Utilisation reduite de paclitaxel grace a l'hyaluronan - Google Patents

Utilisation reduite de paclitaxel grace a l'hyaluronan

Info

Publication number
CA2208924A1
CA2208924A1 CA002208924A CA2208924A CA2208924A1 CA 2208924 A1 CA2208924 A1 CA 2208924A1 CA 002208924 A CA002208924 A CA 002208924A CA 2208924 A CA2208924 A CA 2208924A CA 2208924 A1 CA2208924 A1 CA 2208924A1
Authority
CA
Canada
Prior art keywords
amount
hyaluronan
paclitaxel
dosage amount
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002208924A
Other languages
English (en)
Inventor
Adrian Moore
Samuel S. Asculai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Priority to CA002208924A priority Critical patent/CA2208924A1/fr
Priority to PCT/CA1998/000660 priority patent/WO1999002151A1/fr
Priority to AU82031/98A priority patent/AU8203198A/en
Publication of CA2208924A1 publication Critical patent/CA2208924A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002208924A 1997-07-09 1997-07-09 Utilisation reduite de paclitaxel grace a l'hyaluronan Abandoned CA2208924A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002208924A CA2208924A1 (fr) 1997-07-09 1997-07-09 Utilisation reduite de paclitaxel grace a l'hyaluronan
PCT/CA1998/000660 WO1999002151A1 (fr) 1997-07-09 1998-07-08 Compositions de paclitaxel contenant un acide hyaloronique de poids moleculaire inferieur a 750 000 da
AU82031/98A AU8203198A (en) 1997-07-09 1998-07-08 Paclitaxel compositions containing hyaluronic acid of a molecular weight of lessthan 750.000 da

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002208924A CA2208924A1 (fr) 1997-07-09 1997-07-09 Utilisation reduite de paclitaxel grace a l'hyaluronan

Publications (1)

Publication Number Publication Date
CA2208924A1 true CA2208924A1 (fr) 1999-01-09

Family

ID=4160954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208924A Abandoned CA2208924A1 (fr) 1997-07-09 1997-07-09 Utilisation reduite de paclitaxel grace a l'hyaluronan

Country Status (3)

Country Link
AU (1) AU8203198A (fr)
CA (1) CA2208924A1 (fr)
WO (1) WO1999002151A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534484A (ja) * 1999-01-13 2002-10-15 メディテック リサーチ リミテッド 薬物の効力を増強するための組成物および方法
US8287894B2 (en) 2000-07-14 2012-10-16 Alchemia Oncology Pty Limited Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
NZ520312A (en) 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
IT1318403B1 (it) 2000-03-17 2003-08-25 Cooperativa Ct Ricerche Poly T Esteri polisaccaridici di n-derivati di acido glutammico.
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
AU2003284885A1 (en) * 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
WO2004050057A2 (fr) * 2002-12-04 2004-06-17 Technologies Biolactis Inc. Systeme d'administration a base d'exopolysaccharides pour l'administration de molecules actives
HUE037474T2 (hu) * 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8900422D0 (sv) * 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
CA2122519C (fr) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Traitement du cancer et prevention des metastases
WO1993024476A1 (fr) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Vehicules polymeres solubles dans l'eau servant a la liberation de medicaments
SE9301422D0 (sv) * 1993-04-28 1993-04-28 Kabi Pharmacia Ab Method and means for inhibiting posterior capsule opacification

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534484A (ja) * 1999-01-13 2002-10-15 メディテック リサーチ リミテッド 薬物の効力を増強するための組成物および方法
JP4790911B2 (ja) * 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
US8741970B2 (en) 1999-01-13 2014-06-03 Alchemia Oncology Pty Limited Composition and method for the enhancement of the efficacy of drugs
US8287894B2 (en) 2000-07-14 2012-10-16 Alchemia Oncology Pty Limited Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US8388993B2 (en) 2000-07-14 2013-03-05 Alchemia Oncology Pty Limited Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Also Published As

Publication number Publication date
AU8203198A (en) 1999-02-08
WO1999002151A1 (fr) 1999-01-21

Similar Documents

Publication Publication Date Title
US6537978B1 (en) Oral administration of effective amounts of forms of hyaluronic acid
US6475795B1 (en) Use of hyaluronan in gene therapy
US8778908B2 (en) Cystitis treatment with high dose chondroitin sulfate
CA2122519C (fr) Traitement du cancer et prevention des metastases
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
CA2208924A1 (fr) Utilisation reduite de paclitaxel grace a l'hyaluronan
US5674857A (en) Use of hyaluronic acid to repair ischemia reperfusion damage
CA2175282A1 (fr) Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
US5817642A (en) Clearing of atherosclerosis
JP4210330B2 (ja) ヒアルロン酸レセプター結合剤、およびその使用方法
SA97180188B1 (ar) تركيب وطريقة تحضير الكاربابنيم كمضاد حيوي
US5817644A (en) Targeting of dosages of medicine and therapeutic agents
CA2122551A1 (fr) Traitement de l'atherosclerose
RU2739184C1 (ru) Фармацевтическое средство для лечения артрологических заболеваний
RU2739747C1 (ru) Фармацевтическое средство для лечения артрологических заболеваний
EA041405B1 (ru) Фармацевтическое средство для лечения артрологических заболеваний
EA041409B1 (ru) Фармацевтическое средство для лечения артрологических заболеваний
CA2131130A1 (fr) Modulation de l'activite cellulaire
DE69634993T2 (de) Verwendung von hyaluronan in gentherapie
CA2193921A1 (fr) Administration orale de quantites efficaces de formes d'acide hyaluronique repondant a diverses normes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead